Sanofi teams up with Merck to evaluate THOR-707 and Keytruda in cancer

• Sanofi (NASDAQ:SNY) inks agreement with Merck (NYSE:MRK) to conduct a Phase 2 clinical trial to evaluate the safety, pharmacokinetics, and preliminary efficacy of THOR-707, a highly differentiated non-alpha IL-2 candidate combined with or in sequenced administration with MRK's Keytruda (pembrolizumab) in patients with various cancers.
• Under the agreement, Sanofi will sponsor the clinical trials, while Merck will provide Keytruda. Financial terms are not disclosed.
• The collaboration will enable SNY to explore whether THOR-707 can increase and expand the effectiveness of Keytruda and improve the outcomes for patients with cancer.
• In addition, Sanofi is separately evaluating the activity of this novel biologic in combination with other anti-PD-1 antibodies, including Libtayo, and with anti-EGFR and anti-CD38 antibodies for various types of cancer tumors.
• THOR-707 is currently in a Phase I dose escalation and expansion trial assessing safety and tolerability, and to determine recommended Phase 2 dose alone and in combination with anti-PD-1 and anti-EGFR antibodies.
• https://seekingalpha.com/news/3627955-sanofi-teams-up-merck-to-evaluate-thorminus-707-and-keytruda-in-cancer